Hassan Hartman

Hassan Hartman

Auto-generated profile, based on publicly available information

Hassan Hartman

UK Health Security Agency, Porton Down, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
NPNicole Pearcy
Nicole Pearcy
MGMarco Garavaglia
Marco Garavaglia
TMThomas Millat
Thomas Millat
JGJames P. Gilbert
James P. Gilbert
YSYoseb Song
Yoseb Song
Nigel MintonNigel Minton
Nigel Minton
Exploiting biological processes to recycle renewable carbon into high value platform chemicals provides a sustainable and greener alternative to current reliance on petrochemicals. In this regardCupriavidus necatorH16 represents a particularly promising microbial chassis due to its ability to grow on a wide range of low-cost feedstocks, including the waste gas carbon dioxide, whilst also naturally producing large quantities of polyhydroxybutyrate (PHB) during nutrient-limited conditions. Understanding the complex metabolic behaviour of this bacterium is a prerequisite for the design of successful engineering strategies for optimising product yields. We present a genome-scale metabolic model (GSM) ofC.necatorH16 (denotediCN1361), which is directly constructed from the BioCyc database to improve the readability and reusability of the model. After the initial automated construction, we have performed extensive curation and both theoretical and experimental validation. By carrying out a genome-wide essentiality screening using a Transposon-directed Insertion site Sequencing (TraDIS) approach, we showed that the model could predict gene knockout phenotypes with a high level of accuracy. Importantly, we indicate how experimental and computational predictions can be used to improve model structure and, thus, model accuracy as well as to evaluate potential false positives identified in the experiments. Finally, by integrating transcriptomics data withiCN1361 we create a condition-specific model, which, importantly, better reflects PHB production inC.necatorH16. Observed changes in the omics data andin-silico-estimated alterations in fluxes were then used to predict the regulatory control of key cellular processes. The results presented demonstrate thatiCN1361 is a valuable tool for unravelling the system-level metabolic behaviour ofC.necatorH16 and can provide useful insights for designing metabolic engineering strategies.

27 January 2023 in medRxiv
Verified
Preprint
Open access
PDF file
TSTheo Sanderson
Theo Sanderson
RHRyan Hisner
Ryan Hisner
IDI’ah Donovan-Banfield
I’ah Donovan-Banfield
HHHassan Hartman
Hassan Hartman
ALAlessandra Lochen
Alessandra Lochen
CRChristopher Ruis
Christopher Ruis
Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts by inducing mutations in the virus genome during replication. Most random mutations are likely to be deleterious to the virus, and many will be lethal, and so molnupiravir-induced elevated mutation rates reduce viral load 2,3 . However, if some patients treated with molnupiravir do not fully clear SARS-CoV-2 infections, there could be the potential for onward transmission of molnupiravir-mutated viruses. Here we show that SARS-CoV-2 sequencing databases contain extensive evidence of molnupiravir mutagenesis. Using a systematic approach, we find that a specific class of long phylogenetic branches, distinguished by a high proportion of G-to-A and C-to-T mutations, appear almost exclusively in sequences from 2022, after the introduction of molnupiravir treatment, and in countries and age-groups with widespread usage of the drug. We identify a mutational spectrum, with preferred nucleotide contexts, from viruses in patients known to have been treated with molnupiravir and show that its signature matches that seen in these long branches, in some cases with onwards transmission of molnupiravir-derived lineages. Finally, we analyse treatment records to confirm a direct association between these high G-to-A branches and the use of molnupiravir.

22 July 2026 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
SBSalmaan Bholah
Salmaan Bholah
CDChris Davis
Chris Davis
KSKatherine Smollett
Katherine Smollett
RORichard J Orton
Richard J Orton
TLTemi Lampejo
Temi Lampejo
IIISARIC4C investigators
ISARIC4C investigators
Tecovirimat is widely used for severe mpox, but resistance is increasingly reported, particularly in immunocompromised hosts. We describe a case of persistent clade IIb mpox in a 43-year-old man with advanced HIV (CD4 23 cells/µL) and disseminated necrotising disease. Despite prolonged tecovirimat therapy, lesions progressed. Serial viral isolates (n=8) obtained over 45 days underwent phenotypic susceptibility testing and whole-genome sequencing. Tecovirimat susceptibility declined markedly, with a ∼3 log10 increase in IC50 in late isolates. Sequencing identified distinct resistance-associated VP37 mutations (A290V, A295E), emerging in parallel within heterogeneous viral populations. In vitro passaging confirmed rapid enrichment of resistant phenotypes under drug pressure. Susceptibility to cidofovir and brincidofovir was preserved, and initiation of cidofovir was associated with clinical improvement and cessation of new lesions. This case demonstrates rapid intra-host evolution of multi-lineage tecovirimat resistance in severe mpox, highlighting the need for resistance surveillance and alternative or combination antiviral strategies in immunocompromised patients.